Disclosures for "Intranasal Delivery of TGFα – A Novel Therapeutic Approach for Lesion Resolution in Multiple Sclerosis?")
-
Mrs. Loesslein has nothing to disclose.
-
Mr. Linnerbauer has nothing to disclose.
-
Dr. Tsaktanis has nothing to disclose.
-
Dr. Quintana has nothing to disclose.
-
Prof. Rothhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Rothhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Prof. Rothhammer has received research support from German Research Foundation. The institution of Prof. Rothhammer has received research support from European Research Council.